Baillie Gifford & Co. Sells 40,265 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Baillie Gifford & Co. reduced its holdings in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) by 0.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 15,871,875 shares of the biotechnology company’s stock after selling 40,265 shares during the quarter. Baillie Gifford & Co. owned 6.43% of Adaptimmune Therapeutics worth $25,078,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Key Client Fiduciary Advisors LLC lifted its holdings in shares of Adaptimmune Therapeutics by 6.4% in the fourth quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company’s stock worth $267,000 after acquiring an additional 20,295 shares during the last quarter. Harbor Capital Advisors Inc. boosted its position in Adaptimmune Therapeutics by 9.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 13,317 shares in the last quarter. Twin Focus Capital Partners LLC bought a new stake in shares of Adaptimmune Therapeutics during the fourth quarter worth $44,000. JTC Employer Solutions Trustee Ltd bought a new stake in shares of Adaptimmune Therapeutics during the first quarter worth $41,000. Finally, Columbia Advisory Partners LLC acquired a new position in shares of Adaptimmune Therapeutics during the first quarter worth $25,000. 31.37% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ADAP has been the topic of several recent research reports. Mizuho cut their price objective on Adaptimmune Therapeutics from $9.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, May 17th. Scotiabank began coverage on Adaptimmune Therapeutics in a report on Thursday, May 30th. They set a “sector outperform” rating and a $3.15 price target on the stock. Finally, StockNews.com upgraded shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, June 3rd.

Adaptimmune Therapeutics Price Performance

Shares of Adaptimmune Therapeutics stock traded up $0.20 during midday trading on Friday, reaching $1.22. The company had a trading volume of 3,830,304 shares, compared to its average volume of 1,262,917. The stock has a fifty day moving average price of $1.05 and a 200 day moving average price of $1.11. Adaptimmune Therapeutics plc has a fifty-two week low of $0.42 and a fifty-two week high of $2.05.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Adaptimmune Therapeutics had a negative net margin of 890.13% and a negative return on equity of 259.68%. The firm had revenue of $5.68 million for the quarter, compared to the consensus estimate of $4.40 million. As a group, research analysts expect that Adaptimmune Therapeutics plc will post -0.61 EPS for the current year.

Adaptimmune Therapeutics Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.